Roberta Ambrosini

ORCID: 0000-0002-4082-2303
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Adrenal and Paraganglionic Tumors
  • Cancer, Hypoxia, and Metabolism
  • Glioma Diagnosis and Treatment
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Renal and Vascular Pathologies
  • Spinal Fractures and Fixation Techniques
  • Liver Disease and Transplantation
  • Colorectal Cancer Surgical Treatments
  • Genetic and Kidney Cyst Diseases
  • Pituitary Gland Disorders and Treatments
  • MRI in cancer diagnosis
  • Congenital Anomalies and Fetal Surgery
  • Liver Disease Diagnosis and Treatment
  • Spine and Intervertebral Disc Pathology
  • Radiomics and Machine Learning in Medical Imaging
  • Medical Imaging and Analysis
  • Advanced MRI Techniques and Applications
  • Hormonal Regulation and Hypertension
  • Gallbladder and Bile Duct Disorders
  • Inflammatory Bowel Disease
  • Renal cell carcinoma treatment
  • Vascular Procedures and Complications
  • Microscopic Colitis
  • Congenital gastrointestinal and neural anomalies

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2017-2024

University of Brescia
2019-2020

Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2006-2012

Azienda Ospedaliero Universitaria Maggiore della Carita
2007-2010

University of Chieti-Pescara
1997-1998

PURPOSE: To evaluate the accuracy of contrast material–enhanced multi–detector row computed tomographic (CT) colonography for preoperative staging colorectal cancer. MATERIALS AND METHODS: Forty-one patients with carcinoma underwent contrast-enhanced CT colonography. Images were obtained in arterial (start delay 35 seconds) and portal venous 70 phases. The phase was focused on suspected region neoplasm, whereas included whole abdomen pelvis. Two radiologists independently evaluated depth...

10.1148/radiol.2311021152 article EN Radiology 2004-04-01

Etoposide, doxorubicin and cisplatin plus oral mitotane (EDP-M) comprise the reference regimen in management of patients with adrenocortical carcinoma (ACC). In this paper, we described outcome 58 advanced/metastatic ACC consecutively treated EDP-M a center for rare disease Italy. series, obtained partial response 50% patients; median progression free survival (PFS) overall were 10.1 months (95% Confidence Interval [CI 95%] 8.1–12.8) 18.7 CI: 14.6–22.8), respectively. was not interrupted...

10.3390/cancers12040941 article EN Cancers 2020-04-10

Chest Computed Tomography (CT) imaging has played a central role in the diagnosis of interstitial pneumonia patients affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and can be used to obtain extent lung involvement COVID-19 either qualitatively, via visual inspection, or quantitatively, AI-based software. This study aims compare qualitative/quantitative pathological extension data on patients. Secondly, quantitative obtained were compared verify their concordance...

10.3390/diagnostics12061501 article EN cc-by Diagnostics 2022-06-20

•Cabazitaxel is well tolerated but poorly active as second/third-line treatment in patients with advanced ACC.•Combining RECIST and Choi criteria could be of value the assessment disease response to chemotherapy ACC patients.•Older age, elevated cortisol LDH blood level correlate a greater risk death multivariate analysis. BackgroundAdrenocortical carcinoma (ACC) rare aggressive malignancy poor prognosis. No efficacious options are currently available for metastatic progression standard...

10.1016/j.esmoop.2022.100422 article EN cc-by-nc-nd ESMO Open 2022-03-07

We evaluated tumor response at Computed Tomography (CT) according to three radiologic criteria: RECIST 1.1, CHOI and volume in 34 patients with metastatic adrenocortical carcinoma (ACC) submitted standard chemotherapy. These criteria agreed defining partial response, stable or progressive disease 24 (70.5%). Partial (PR) was observed 29.4%, 29.4% 41.2% of volume, respectively. It associated a favorable prognosis, regardless the criterion adopted. The concordance all 3 identified 8 (23.5%)...

10.3390/cancers12061395 article EN Cancers 2020-05-28

Gemcitabine plus Capecitabine (Gem/Cape) is a frequently adopted second line chemotherapy for metastatic adrenocortical carcinoma (ACC), but only minority of patients destined to obtain clinical benefit. The identification baseline predictive factors efficacy relevant. We retrospectively analyzed data from 50 consecutive with progressing ACC treated between 2011 and 2019. Patients received intravenous oral on metronomic schedule. Previous mitotane therapy was maintained. Clinical benefit...

10.3389/fendo.2021.624102 article EN cc-by Frontiers in Endocrinology 2021-02-24

(1) Background: The standard first-line therapy for advanced adrenocortical carcinoma (ACC) is represented by EDP-M (etoposide, doxorubicin, cisplatin + mitotane). Progestins have shown cytotoxic activity both in vitro and vivo on ACC; better tolerability efficacy been hypnotized due to the association with progestins. (2) Methods: feasibility of combined oral megestrol acetate (EDP-MM) were tested 24 patients (pts) affected metastatic ACC a low performance status (PS); case group was...

10.3390/cancers15184491 article EN Cancers 2023-09-09

Secondary peritoneal hydatidosis is caused by spontaneous or iatrogenic rupture of hepatic echinococcal cysts. We describe the case a 65-year-old Tunisian male patient with previous history liver who presented to our attention subocclusive status. Imaging revealed retrovesical hydatid cyst, adherent sigmoid colon. The treatment choice was surgical removal cyst and now being closely followed up.

10.1155/2010/714106 article EN cc-by Case Reports in Medicine 2010-01-01
Coming Soon ...